Mohamed Skiba

Dr. Mohamed Skiba

Associate Professor, UFR Medecine-Pharmacie, Pharmacie Galénique et de Biopharmacie, 22 Bd Gambetta, CEDEX, 76183 Rouen, France
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
AHAktham Hassan
Aktham Hassan
AIAyman Ibrahim
Ayman Ibrahim
KMKhaly Mbodji
Khaly Mbodji
MCMoise Coëffier
Moise Coëffier
FZFrédéric Ziegler
Frédéric Ziegler
RMRachel Marion-Letellier
Rachel Marion-Letellier
We have previously shown that α-linolenic acid (ALA), a (n-3) PUFA exerts in vitro antiinflammatory effects in the intestine. In this study, we aimed

1 April 2016 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
Abdeslam CHAGRAOUIAbdeslam CHAGRAOUI
Abdeslam CHAGRAOUI
FTF. Thibaut
F. Thibaut
MSMohamed Skiba
Mohamed Skiba
CTC. Thuillez
C. Thuillez
MBM. Bourin
M. Bourin

16 November 2018 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LMLyes MEHENNI
Lyes MEHENNI
MLMalika Lahiani-skiba
Malika Lahiani-skiba
GLGuy Ladam
Guy Ladam
FHFrançois Hallouard
François Hallouard
MSMohamed Skiba
Mohamed Skiba
In the present study, new polymer microspheres of amphotericin B (AmB) were prepared by a spray drying technique using cyclodextrin polymers (Poly-CD) to improve the solubility and dissolution of AmB, to prevent in vivo toxic AmB aggregations. Formulations were characterized through scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC), thermal analysis, Raman spectroscopy, particle size, drug purity test and in vitro release studies. The analysis indicated that the chemical structure of AmB remained unchanged in the amorphous solid dispersion, but the structure was changed from crystalline to amorphous. AmB was completely release from such optimized formulations in dissolution media in 40 min. This work may contribute to a new generation of spherical amorphous solid dispersion using a cyclodextrin polymer, which has implications for the possibility of drug development for oral utilization or as powder aerosols for pulmonary administration.

1 May 2015 in Chemical Engineering Research and Design
Verified
Journal Article
Closed access
LML. Moulahcene
L. Moulahcene
MSMohamed Skiba
Mohamed Skiba
OSO. Senhadji
O. Senhadji
NMN. Milon
N. Milon
MBM. Benamor
M. Benamor
MLM. Lahiani-Skiba
M. Lahiani-Skiba

1 March 2000 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MSMohamed Skiba
Mohamed Skiba
MSM. Skiba-Lahiani
M. Skiba-Lahiani
HMH. Marchais
H. Marchais
RDR. Duclos
R. Duclos
PAP. Arnaud
P. Arnaud

18 October 2016 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
FHFrancois Hallouard
Francois Hallouard
LMLyes Mehenni
Lyes Mehenni
MLMalika Lahiani-Skiba
Malika Lahiani-Skiba
YAYoussef Anouar
Youssef Anouar
MSMohamed Skiba
Mohamed Skiba
Oral drug delivery remains the most physiological and therefore the most preferred, simplest and easiest administration route. Nevertheless, a multitude of potentially clinically important drugs will not reach the market or achieve their full potential unless their oral bioavailability is improved by formulation. The aim of this review is to present an overview of properties, formulation, excipients and characterization of solid dispersions corresponding to one of the different formulation strategies for design and development of poorly soluble drugs. This work will review and compare in detail the evolution of solid dispersions focused on the different methods of formulation and production of solid dispersions, their stability, their release properties, their pharmacokinetics and methods for their physicochemical characterization.